The Brown Capital Management Small Company Fund Bets on Krystal Biotech (KRYS) for Its Resilient Revenue Stream

Brown Capital Management's Small Company Fund significantly underperformed in Q1 2026, declining 19.78% compared to the Russell 2000 Growth index's more modest 2.81% decline. This substantial performance gap indicates the fund's positioning in smaller-cap growth equities exposed concentrated losses during a period of broad small-cap volatility, with KRYS highlighted as a core holding despite headwinds.

The fund's emphasis on Krystal Biotech reflects a conviction-based strategy targeting companies with resilient revenue streams—a rationale suggesting management views the biotech name as possessing defensive characteristics within an otherwise volatile small-cap growth universe. However, the fund's underperformance relative to its benchmark underscores the challenge of value creation in this segment during uncertain macro conditions.

Small-cap growth equities typically exhibit higher volatility and sector concentration risk than broad market indices. KRYS operates in biotechnology, a segment sensitive to regulatory approvals, clinical trial outcomes, and broader healthcare spending dynamics. The fund's positioning reflects a bet that smaller biotech firms with demonstrated revenue generation can outperform despite near-term market dislocations.

Sector implication: Health Care small-caps face headwinds from growth investor rotation and macro uncertainty. The persistence of KRYS in small-cap focused portfolios suggests contrarian positioning, though Q1 results highlight execution risk in proving fundamental resilience amid broader market repricing of growth valuations.